Ramez Kouzy

Dr. Ramez Kouzy

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2020 in Cureus
Verified
Journal Article
Open access
PDF file
RKRamez Kouzy
Ramez Kouzy
JJJoseph Abi Jaoude
Joseph Abi Jaoude
AKAfif Kraitem
Afif Kraitem
MAMolly B. El Alam
Molly B. El Alam
BKBasil Karam
Basil Karam
KBKhalil Baddour
Khalil Baddour
Since the beginning of the coronavirus disease 2019 (COVID-19) epidemic, misinformation has been spreading uninhibited over traditional and social media at a rapid pace. We sought to analyze the magnitude of misinformation that is being spread on Twitter (Twitter, Inc., San Francisco, CA) regarding the coronavirus epidemic. We conducted a search on Twitter using 14 different trending hashtags and keywords related to the COVID-19 epidemic. We then summarized and assessed individual tweets for misinformation in comparison to verified and peer-reviewed resources. Descriptive statistics were used to compare terms and hashtags, and to identify individual tweets and account characteristics. The study included 673 tweets. Most tweets were posted by informal individuals/groups (66%), and 129 (19.2%) belonged to verified Twitter accounts. The majority of included tweets contained serious content (91.2%); 548 tweets (81.4%) included genuine information pertaining to the COVID-19 epidemic. Around 70% of the tweets tackled medical/public health information, while the others were pertaining to sociopolitical and financial factors. In total, 153 tweets (24.8%) included misinformation, and 107 (17.4%) included unverifiable information regarding the COVID-19 epidemic. The rate of misinformation was higher among informal individual/group accounts (33.8%, p: <0.001). Tweets from unverified Twitter accounts contained more misinformation (31.0% vs 12.6% for verified accounts, p: <0.001). Tweets from healthcare/public health accounts had the lowest rate of unverifiable information (12.3%, p: 0.04). The number of likes and retweets per tweet was not associated with a difference in either false or unverifiable content. The keyword “COVID-19” had the lowest rate of misinformation and unverifiable information, while the keywords “#2019_ncov” and “Corona” were associated with the highest amount of misinformation and unverifiable content respectively. Medical misinformation and unverifiable content pertaining to the global COVID-19 epidemic are being propagated at an alarming rate on social media. We provide an early quantification of the magnitude of misinformation spread and highlight the importance of early interventions in order to curb this phenomenon that endangers public safety at a time when awareness and appropriate preventive actions are paramount.

4 June 2020 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
Daniel LinDaniel Lin
Daniel Lin
RKRamez Kouzy
Ramez Kouzy
JJJoseph Abi Jaoude
Joseph Abi Jaoude
SNSonal S Noticewala
Sonal S Noticewala
AMAndrea Y Delgado Medrano
Andrea Y Delgado Medrano
LCLauren E Colbert
Lauren E Colbert

4 March 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MAMolly B. El Alam
Molly B. El Alam
TSTravis T. Sims
Travis T. Sims
RKRamez Kouzy
Ramez Kouzy
GBGreyson W. G. Biegert
Greyson W. G. Biegert
JJJoseph A. B. I. Jaoude
Joseph A. B. I. Jaoude
LCLauren E. Colbert
Lauren E. Colbert
Background: A diverse and abundant gut microbiome can improve cancer patients’ treatment response; however, the effect of pelvic chemoradiotherapy (CRT) on gut diversity and composition is unclear. The purpose of this prospective study was to identify changes in the diversity and composition of the gut microbiome during and after pelvic CRT. Materials and methods: Rectal swabs from 58 women with cervical, vaginal, or vulvar cancer from two institutions were prospectively analyzed before CRT (baseline), during CRT (weeks 1, 3, and 5), and at first follow-up (week 12) using 16Sv4 rRNA gene sequencing of the V4 hypervariable region of the bacterial 16S rRNA marker gene. 42 of these patients received antibiotics during the study period. Observed operational taxonomic units (OTUs; representative of richness) and Shannon, Simpson, Inverse Simpson, and Fisher diversity indices were used to characterize alpha (within-sample) diversity. Changes over time were assessed using a paired t-test, repeated measures ANOVA, and linear mixed modeling. Compositional changes in specific bacteria over time were evaluated using linear discriminant analysis effect size. Results: Gut microbiome richness and diversity levels continually decreased throughout CRT (mean Shannon diversity index, 2.52 vs. 2.91; all P <0.01), but were at or near baseline levels in 60% of patients by week 12. Patients with higher gut diversity at baseline had the steepest decline in gut microbiome diversity. Gut microbiome composition was significantly altered during CRT, with increases in Proteobacteria and decreases in Clostridiales, but adapted after CRT, with increases in Bacteroides species. Conclusion: After CRT, the diversity of the gut microbiomes in this population tended to return to baseline levels by the 12 week follow-up period, but structure and composition remained significantly altered. These changes should be considered when designing studies to analyze the gut microbiome in patients who receive pelvic CRT for gynecologic cancers.

1 December 2020 in Current Problems in Cancer
Verified
Journal Article
Closed access
JJJoseph Abi Jaoude
Joseph Abi Jaoude
RKRamez Kouzy
Ramez Kouzy
NNNicholas Nguyen
Nicholas Nguyen
Daniel LinDaniel Lin
Daniel Lin
SNSonal S. Noticewala
Sonal S. Noticewala
Cullen M. TaniguchiCullen M. Taniguchi
Cullen M. Taniguchi

25 November 2021 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
KCKelsey L. Corrigan
Kelsey L. Corrigan
SKStephen Kry
Stephen Kry
RHRebecca M. Howell
Rebecca M. Howell
RKRamez Kouzy
Ramez Kouzy
JJJoseph Abi Jaoude
Joseph Abi Jaoude
ELEthan Ludmir
Ethan Ludmir

1 July 2020 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
RKRamez Kouzy
Ramez Kouzy
JJJoseph Abi Jaoude
Joseph Abi Jaoude
CGCarolina J. Garcia Garcia
Carolina J. Garcia Garcia
MAMolly B. El Alam
Molly B. El Alam
Cullen M. TaniguchiCullen M. Taniguchi
Cullen M. Taniguchi
ELEthan Ludmir
Ethan Ludmir
High-quality evidence generated by appropriately powered and controlled trials is needed to advance care for patients with coronavirus disease 2019 (COVID-19) and those who are susceptible to it.1,2 In the midst of the COVID-19 pandemic, multiple similar therapeutic trials are being conducted in parallel, potentially reducing participant accrual across trials. In this systematic review, we characterize the landscape of current COVID-19 trials to better quantify these potential issues.